| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
9,831 |
6,761 |
$3.36M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
12,508 |
10,521 |
$3.08M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
13,316 |
11,679 |
$2.36M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,265 |
2,843 |
$1.13M |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,101 |
2,567 |
$681K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,920 |
1,682 |
$576K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,347 |
3,945 |
$484K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
10,840 |
2,644 |
$465K |
| 87631 |
|
3,496 |
3,206 |
$389K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,556 |
6,961 |
$349K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
893 |
732 |
$332K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
14,868 |
6,243 |
$331K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
10,888 |
7,185 |
$317K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,101 |
5,398 |
$277K |
| 71045 |
Radiologic examination, chest; single view |
6,028 |
4,924 |
$248K |
| 80053 |
Comprehensive metabolic panel |
20,439 |
14,314 |
$192K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,805 |
2,145 |
$171K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,402 |
2,919 |
$166K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
6,544 |
4,708 |
$165K |
| 71046 |
Radiologic examination, chest; 2 views |
3,199 |
2,633 |
$160K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,297 |
1,683 |
$158K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
673 |
578 |
$154K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,745 |
3,336 |
$131K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
18,576 |
14,853 |
$125K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
4,817 |
1,768 |
$124K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,736 |
1,649 |
$122K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,885 |
1,487 |
$103K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
645 |
596 |
$98K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,715 |
2,677 |
$97K |
| 36415 |
Collection of venous blood by venipuncture |
21,208 |
11,400 |
$89K |
| 87634 |
|
3,521 |
3,225 |
$87K |
| 73610 |
|
686 |
575 |
$85K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
232 |
213 |
$85K |
| 96376 |
|
1,843 |
1,345 |
$80K |
| 72100 |
|
961 |
804 |
$79K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,262 |
1,503 |
$75K |
| 73630 |
|
721 |
619 |
$75K |
| G0378 |
Hospital observation service, per hour |
1,345 |
668 |
$74K |
| 84484 |
|
6,518 |
4,864 |
$71K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,629 |
2,216 |
$67K |
| 83880 |
|
2,568 |
2,016 |
$66K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
292 |
251 |
$65K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,433 |
1,190 |
$55K |
| 97161 |
|
1,111 |
920 |
$48K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,102 |
5,761 |
$44K |
| 84703 |
|
6,264 |
5,497 |
$43K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
627 |
411 |
$39K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,385 |
2,218 |
$37K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
186 |
173 |
$36K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,799 |
3,222 |
$35K |
| 83690 |
|
5,896 |
5,064 |
$35K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,194 |
444 |
$35K |
| 73130 |
|
542 |
455 |
$34K |
| 81001 |
|
11,099 |
9,215 |
$34K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,964 |
3,487 |
$30K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,137 |
1,004 |
$30K |
| 93971 |
|
263 |
239 |
$29K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,411 |
3,893 |
$24K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,704 |
1,517 |
$23K |
| J2704 |
Injection, propofol, 10 mg |
2,430 |
2,130 |
$22K |
| 73030 |
|
377 |
290 |
$22K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,660 |
2,675 |
$21K |
| 82553 |
|
1,714 |
1,289 |
$21K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,073 |
940 |
$20K |
| 71250 |
|
178 |
135 |
$20K |
| 83605 |
|
2,065 |
1,628 |
$19K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,529 |
2,137 |
$19K |
| 72040 |
|
246 |
191 |
$18K |
| 83735 |
|
2,913 |
2,281 |
$16K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
408 |
117 |
$16K |
| 82947 |
|
2,591 |
1,539 |
$15K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
539 |
499 |
$15K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
434 |
392 |
$14K |
| 82550 |
|
2,261 |
1,716 |
$14K |
| 87077 |
|
1,689 |
1,478 |
$14K |
| 87081 |
|
1,711 |
1,529 |
$12K |
| 73560 |
|
173 |
142 |
$11K |
| 85610 |
|
3,128 |
2,550 |
$11K |
| 87040 |
|
944 |
598 |
$11K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,285 |
1,089 |
$11K |
| 85730 |
|
2,394 |
2,050 |
$11K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,342 |
999 |
$10K |
| 94060 |
|
103 |
67 |
$10K |
| 74018 |
|
291 |
254 |
$10K |
| 85379 |
|
1,086 |
998 |
$10K |
| 85027 |
|
1,431 |
1,108 |
$10K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,101 |
867 |
$9K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
15 |
12 |
$8K |
| 94760 |
|
1,633 |
999 |
$8K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,887 |
1,657 |
$8K |
| 82565 |
|
596 |
359 |
$8K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,249 |
1,112 |
$8K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,449 |
1,126 |
$7K |
| 90715 |
|
249 |
229 |
$7K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
13 |
12 |
$7K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
343 |
309 |
$7K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
490 |
154 |
$7K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
576 |
498 |
$6K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
174 |
157 |
$6K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
47 |
42 |
$5K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
92 |
29 |
$5K |
| 82805 |
|
85 |
64 |
$4K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
481 |
393 |
$4K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
17 |
13 |
$4K |
| 87186 |
|
517 |
439 |
$4K |
| 73110 |
|
62 |
54 |
$4K |
| 82150 |
|
585 |
506 |
$4K |
| 80061 |
Lipid panel |
292 |
263 |
$3K |
| 73562 |
|
33 |
24 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
379 |
327 |
$3K |
| J3490 |
Unclassified drugs |
696 |
326 |
$3K |
| 86328 |
|
79 |
76 |
$3K |
| 93017 |
|
14 |
12 |
$2K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
414 |
373 |
$2K |
| 12001 |
|
25 |
24 |
$2K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
330 |
293 |
$2K |
| 97116 |
|
55 |
26 |
$2K |
| 93225 |
|
14 |
12 |
$2K |
| C9113 |
Injection, pantoprazole sodium, per vial |
172 |
142 |
$2K |
| 76536 |
|
14 |
12 |
$2K |
| J2060 |
Injection, lorazepam, 2 mg |
238 |
184 |
$2K |
| 81003 |
|
720 |
623 |
$2K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
792 |
726 |
$2K |
| 86141 |
|
191 |
150 |
$2K |
| 87210 |
|
388 |
183 |
$2K |
| 94726 |
|
29 |
24 |
$2K |
| 84145 |
|
65 |
61 |
$1K |
| 73080 |
|
16 |
14 |
$1K |
| 87807 |
|
97 |
92 |
$1K |
| 73502 |
|
21 |
16 |
$1K |
| 94729 |
|
47 |
39 |
$1K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
289 |
248 |
$987.68 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
26 |
25 |
$960.29 |
| 84100 |
|
198 |
156 |
$881.72 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
31 |
24 |
$792.63 |
| 84702 |
|
52 |
42 |
$777.58 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
251 |
207 |
$776.27 |
| 88304 |
|
12 |
12 |
$775.91 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
30 |
12 |
$774.83 |
| 93922 |
|
13 |
12 |
$644.29 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
26 |
24 |
$599.47 |
| J7050 |
Infusion, normal saline solution, 250 cc |
36 |
19 |
$476.04 |
| 86677 |
|
29 |
27 |
$470.81 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
71 |
67 |
$402.15 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
213 |
170 |
$380.52 |
| J1790 |
Injection, droperidol, up to 5 mg |
39 |
38 |
$338.95 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
27 |
12 |
$309.35 |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
17 |
15 |
$267.90 |
| 36600 |
|
15 |
14 |
$252.43 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
31 |
27 |
$146.26 |
| 80076 |
|
18 |
16 |
$117.68 |
| 93242 |
|
13 |
12 |
$106.90 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
16 |
13 |
$93.36 |
| 84439 |
|
12 |
12 |
$83.61 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
12 |
12 |
$80.15 |
| 84132 |
|
12 |
12 |
$51.34 |
| 86900 |
|
13 |
13 |
$40.83 |
| 86901 |
|
13 |
13 |
$40.83 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
42 |
39 |
$33.21 |
| A9270 |
Non-covered item or service |
485 |
86 |
$0.00 |